Microbiology and Immunology
HSF-1, 322 E
Education and Training
- B.Sc. - Biological Sciences, University of Birmingham, UK (1981)
- Ph.D. - Genetics/Microbiology, University of Leicester, UK (1985)
- Postdoc - Department of Microbiology and Immunology, University of North Carolina at Chapel Hill (Dr. P. Frederick Sparling) (1985-1989)
- European Community Senior Postdoctoral Fellowship - Sclavo Research Center, Siena, Italy (Dr. Rino Rappuoli) (1989-1991)
Dr. Carbonetti started working on pertussis with Dr. Rino Rappuoli at Sclavo Research Centre, Siena, Italy in 1989. In 1991 Dr. Carbonetti was hired to his current position as a faculty member in the Department of Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore. His research is primarily on the basic biology of pertussis infection and disease in mouse models, with a focus on the role of pertussis toxin.
Currently his group is investigating mechanisms by which pertussis toxin exacerbates pertussis infection and disease, through (i) upregulation of host factors that contribute to pathogenesis and (ii) inhibition of host mechanisms of attenuating and resolving airway inflammation. This has led to two different therapeutic possibilities that his group is testing in preclinical models, utilizing drugs that are either already FDA approved for other diseases or in clinical trials for treatment of inflammatory conditions. Dr. Carbonetti had the honor of organizing and hosting the ninth International Bordetella Symposium in Baltimore in Sept-Oct, 2010.
Dr. Carbonetti served as program director for the Molecular Microbiology and Immunology graduate program at the University of Maryland School of Medicine from 2005-2015. He is also an editor for the journal Pathogens and Disease and serves on the editorial board for the journal Infection and Immunity. He has also served on numerous NIH study sections.
Bordetella, pertussis, respiratory infection, host response, lung inflammation, sphingosine-1-phosphate receptor signaling, pendrin, adult and neonatal mouse models, interferons
Skerry, C, Scanlon, KM, Ardanuy, JG, Roberts, D, Zhang, L, Rosen, H, Carbonetti, NH (2017) Reduction of pertussis inflammatory pathology by therapeutic treatment with sphingosine-1-phosphate receptor ligands by a pertussis toxin-insensitive mechanism. Journal of Infectious Diseases 215:278-286
Carbonetti, NH (2016) Pertussis leukocytosis: mechanisms, clinical relevance and treatment. Pathogens and Disease 74:ftw087
Plaut, RD, Scanlon, KM, Taylor, M, Teter, K, Carbonetti, NH (2016) Intracellular disassembly and activity of pertussis toxin require interaction with ATP. Pathogens and Disease 74:ftw065
Carbonetti, NH (2015) Contribution of pertussis toxin to the pathogenesis of pertussis disease. Pathogens and Disease 73:ftv073 PMCID: PMC4626579
Skerry, C, Scanlon, KM, Rosen, H, Carbonetti, NH (2015) Sphingosine-1-phosphate receptor agonism reduces Bordetella pertussis-mediated lung pathology. Journal of Infectious Diseases 211:1883-1886 PMCID: PMC4836722
Scanlon, KM, Gau, Y, Skerry, C, Soleimani, M, Wall, SM, Carbonetti, NH (2014) The epithelial anion transporter pendrin contributes to inflammatory lung pathology in Bordetella pertussis infection. Infection & Immunity 82:4212-4221 PMCID: PMC4187853
Carbonetti, NH, Wirsing von König, CH, Lan, R, Jacob-Dubuisson, F, Cotter, PA, Deora, R, Merkel, TJ, van Els, CA, Locht, C, Hozbor, D, Rodriguez, ME (2016) Highlights of the 11th International Bordetella Symposium: From Basic Biology to Vaccine Development. Clinical and Vaccine Immunology 23(11):
Wang, X, Shaw, DK, Hammond, HL, Sutterwala, FS, Rayamajhi, M, Shirey, KA, Perkins, DJ, Bonventre, JV, Velayutham, TS, Evans, SM, Rodino, KG, VieBrock, L, Scanlon, KM, Carbonetti, NH, Carlyon, JA, Miao, EA, McBride, JW, Kotsyfakis, M, Pedra, JHF (2016) The prostaglandin E2-EP3 receptor axis regulates Anaplasma phagocytophilum-mediated NLRC4 inflammasome activation. PLoS Pathogens 12:e1005803 PMCID: PMC4970705
Carbonetti, NH (2016) Bordetella pertussis: New concepts in pathogenesis and treatment. Current Opinion in Infectious Diseases 29:287-294 PMCID: PMC4846492
Guevara, C, Mooi, FR, Greenberg, DP, Decker, MD, Carbonetti, N, Starner, TD, McCray, PB, Iqbal, J, Gómez-Duarte, OG (2016) Primary human airway epithelial cells: a model to study Bordetella pertussis fimbrial-mediated adherence. Infectious Diseases 48:177-188
Scanlon, KM, Skerry, C, Carbonetti, NH (2015) Novel therapies for the treatment of whooping cough. Pathogens and Disease 73:ftv074 PMCID: PMC4626598
Connelly, C, Sun, Y, Carbonetti, NH (2012) Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection. Infection & Immunity 80:4317-4332 PMCID: PMC3497438
Worthington, ZEV, van Rooijen, N, Carbonetti, NH (2011) Enhancement of Bordetella parapertussis infection by Bordetella pertussis in mixed infection of the respiratory tract. FEMS Immunology and Medical Microbiology 63:119-128 PMCID: PMC3170498
Ayala, VI, Teijaro, JR, Farber, DL, Dorsey, SG, Carbonetti, NH (2011) Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS ONE 6(4): e19016 PMCID: PMC3080395
We are interested in the pathogenesis of infection and disease caused by Bordetella pertussis, the agent of pertussis or whooping cough. We use animal models and in vitro approaches to investigate this host-pathogen interaction, with an emphasis on the host response. Current projects include the following:
- Role of pendrin in lung inflammatory pathology caused by Bordetella pertussis infection. We identified mouse lung gene expression specifically associated with pertussis toxin (PT) activity during peak B. pertussis infection. One of the most highly upregulated genes encodes an epithelial anion transporter called pendrin (Slc26a4), also highly upregulated in asthma. Mice deficient in pendrin or mice treated with the pendrin inhibitor acetazolamide had significantly reduced lung inflammatory pathology during B. pertussis infection, identifying a possible new therapeutic target for pertussis treatment.
- Sphingosine-1-phosphate receptors as potential therapeutic targets for treatment of pertussis. Sphingosine-1-phosphate (S1P) signals through G protein-coupled receptors (GPCRs) that are sensitive to PT inhibition. We hypothesized that PT inhibits signaling through this receptor that would normally attenuate inflammation after infection, thereby exacerbating inflammation. Treatment of B. pertussis-infected mice with S1P receptor ligands dramatically reduced cytokine production and lung inflammatory pathology, and treatment of B. pertussis-infected neonatal mice reduced lethality, identifying another potential therapeutic avenue for pertussis treatment. However, these effects were not inhibited by PT, and we are currently attempting to dissect the molecular mechanism by which these ligands cause their effect.
- Neonatal mice infection with Bordetella pertussis as a model of critical pertussis in human infants. As in humans, neonatal mice are susceptible to fatal B. pertussis infection. We found that this lethality is completely dependent on PT activity and that the pathogenesis of disease is quite different from that caused by B. pertussis infection in adult mice.
5/15/13 - 4/30/18
Exacerbation of pertussis airway inflammation and pathology by pertussis toxin
6/15/15 - 5/31/17
Sphingosine-1-phosphate signaling in pertussis pathogenesis and therapeutics
1/1/16 - 12/31/17
Host-targeted therapeutics for pertussis in infants
1/1/16 - 12/31/17
Role of maternal and infant vaccine-induced IgG in protection against pertussis (Role: Collaborator)
- 2017-present: Deputy Editor-in-chief, Pathogens and Disease
- 2017: Chair, ZGM1 MBRS-SCORE Study Section, NIH
- 2016: Scientific Organizing Committee, 11th International Bordetella Symposium, Buenos Aires, Argentina, April 5-8, 2016 – Chair, Immune Responses session; Chair, Pertussis Vaccines Roundtable Discussion session
- 2014: Chair, ZGM1 MBRS-SCORE Study Section, NIH
- 2013-present: Editor, Pathogens and Disease
- 2010: Organizing Committee Chair and Host, 9th International Bordetella Symposium, Baltimore, MD, Sept 30 - Oct 3, 2010
- 2009-present: Editorial Board Member, Infection and Immunity